![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan
Pitavastatin, a novel potent 3-hydroxymethylglutaryl coenzyme A reductase inhibitor, is distributed selectively to the liver and excreted into bile in unchanged form in rats. We reported previously that the hepatic uptake is mainly mediated by organic anion transporting polypeptide (OATP) 1B1, whereas the biliary excretion mechanism remains to be clarified. In the present study, we investigated the role of breast cancer resistance protein (BCRP) in the biliary excretion of pitavastatin. The ATP-dependent uptake of pitavastatin by human and mouse BCRP-expressing membrane vesicles was significantly higher compared with that by control vesicles with Km values of 5.73 and 4.77 µM, respectively. The biliary excretion clearance of pitavastatin in Bcrp1(-/-) mice was decreased to one-tenth of that in control mice. The biliary excretion of pitavastatin was unchanged between control and Eisai hyperbilirubinemic rats, indicating a minor contribution of multidrug resistance-associated protein (Mrp) 2. This observation differs radically from that for a more hydrophilic statin, pravastatin, of which biliary excretion is largely mediated by Mrp2. These data suggest that the biliary clearance of pitavastatin can be largely accounted for by BCRP in mice. In the case of humans, transcellular transport of pitavastatin was determined in the Madin-Darby canine kidney II cells expressing OATP1B1 and human canalicular efflux transporters. A significant basal-to-apical transport of pitavastatin was observed in OATP1B1/MDR1 and OATP1B1/MRP2 double transfectants as well as OATP1B1/BCRP double transfectants, implying the involvement of multiple transporters in the biliary excretion of pitavastatin in humans. This is in contrast to a previous belief that the biliary excretion of statins is mediated mainly by MRP2.
Address correspondence to: Dr. Yuichi Sugiyama, Department of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan. E-mail: sugiyama{at}mol.f.u-tokyo.ac.jp
This article has been cited by other articles:
|
|
 |
|
  K. He, M. W. Lago, R. A. Iyer, W.-C. Shyu, W. G. Humphreys, and L. J. Christopher Lacteal Secretion, Fetal and Maternal Tissue Distribution of Dasatinib in Rats Drug Metab. Dispos., December 1, 2008; 36(12): 2564 - 2570. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Verhulst, R. Sayer, M. E. De Broe, P. C. D'Haese, and C. D. A. Brown Human Proximal Tubular Epithelium Actively Secretes but Does Not Retain Rosuvastatin Mol. Pharmacol., October 1, 2008; 74(4): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J. L. Stock, X. Liu, J. Shi, J. W. Van Deusen, D. A. DiMattia, R. G. Dullea, and S. M. de Morais Utility of a Novel Oatp1b2 Knockout Mouse Model for Evaluating the Role of Oatp1b2 in the Hepatic Uptake of Model Compounds Drug Metab. Dispos., September 1, 2008; 36(9): 1840 - 1845. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Abe, A. S. Bridges, W. Yue, and K. L. R. Brouwer In Vitro Biliary Clearance of Angiotensin II Receptor Blockers and 3-Hydroxy-3-methylglutaryl-Coenzyme A Reductase Inhibitors in Sandwich-Cultured Rat Hepatocytes: Comparison with in Vivo Biliary Clearance J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 983 - 990. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Fukuda, R. Ohashi, M. Tsuda-Tsukimoto, and I. Tamai Effect of Plasma Protein Binding on in Vitro-in Vivo Correlation of Biliary Excretion of Drugs Evaluated by Sandwich-Cultured Rat Hepatocytes Drug Metab. Dispos., July 1, 2008; 36(7): 1275 - 1282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Enokizono, H. Kusuhara, A. Ose, A. H. Schinkel, and Y. Sugiyama Quantitative Investigation of the Role of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Limiting Brain and Testis Penetration of Xenobiotic Compounds Drug Metab. Dispos., June 1, 2008; 36(6): 995 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsushima, K. Maeda, H. Hayashi, Y. Debori, A. H. Schinkel, J. D. Schuetz, H. Kusuhara, and Y. Sugiyama Involvement of Multiple Efflux Transporters in Hepatic Disposition of Fexofenadine Mol. Pharmacol., May 1, 2008; 73(5): 1474 - 1483. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Matsushima, K. Maeda, N. Ishiguro, T. Igarashi, and Y. Sugiyama Investigation of the Inhibitory Effects of Various Drugs on the Hepatic Uptake of Fexofenadine in Humans Drug Metab. Dispos., April 1, 2008; 36(4): 663 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ishiguro, K. Maeda, A. Saito, W. Kishimoto, S. Matsushima, T. Ebner, W. Roth, T. Igarashi, and Y. Sugiyama Establishment of a Set of Double Transfectants Coexpressing Organic Anion Transporting Polypeptide 1B3 and Hepatic Efflux Transporters for the Characterization of the Hepatobiliary Transport of Telmisartan Acylglucuronide Drug Metab. Dispos., April 1, 2008; 36(4): 796 - 805. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Kalgutkar, B. Feng, H. T. Nguyen, K. S. Frederick, S. D. Campbell, H. L. Hatch, Y.-A. Bi, D. C. Kazolias, R. E. Davidson, R. J. Mireles, et al. Role of Transporters in the Disposition of the Selective Phosphodiesterase-4 Inhibitor (+)-2-[4-({[2-(Benzo[1,3]dioxol-5-yloxy)-pyridine-3-carbonyl]-amino}-methyl)-3-fluoro-phenoxy]-propionic Acid in Rat and Human Drug Metab. Dispos., November 1, 2007; 35(11): 2111 - 2118. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Ando, H. Kusuhara, G. Merino, A. I. Alvarez, A. H. Schinkel, and Y. Sugiyama Involvement of Breast Cancer Resistance Protein (ABCG2) in the Biliary Excretion Mechanism of Fluoroquinolones Drug Metab. Dispos., October 1, 2007; 35(10): 1873 - 1879. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, J. Lin, T. Smolarek, and L. Tremaine P-glycoprotein Has Differential Effects on the Disposition of Statin Acid and Lactone Forms in mdr1a/b Knockout and Wild-Type Mice Drug Metab. Dispos., October 1, 2007; 35(10): 1725 - 1729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Enokizono, H. Kusuhara, and Y. Sugiyama Effect of Breast Cancer Resistance Protein (Bcrp/Abcg2) on the Disposition of Phytoestrogens Mol. Pharmacol., October 1, 2007; 72(4): 967 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Yamagata, H. Kusuhara, M. Morishita, K. Takayama, H. Benameur, and Y. Sugiyama Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients Drug Metab. Dispos., July 1, 2007; 35(7): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Enokizono, H. Kusuhara, and Y. Sugiyama Regional Expression and Activity of Breast Cancer Resistance Protein (Bcrp/Abcg2) in Mouse Intestine: Overlapping Distribution with Sulfotransferases Drug Metab. Dispos., June 1, 2007; 35(6): 922 - 928. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Enokizono, H. Kusuhara, and Y. Sugiyama Involvement of Breast Cancer Resistance Protein (BCRP/ABCG2) in the Biliary Excretion and Intestinal Efflux of Troglitazone Sulfate, the Major Metabolite of Troglitazone with a Cholestatic Effect Drug Metab. Dispos., February 1, 2007; 35(2): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Liu, Y. Cui, A. Y. Chung, Y. Shitara, Y. Sugiyama, D. Keppler, and K. S. Pang Vectorial Transport of Enalapril by Oatp1a1/Mrp2 and OATP1B1 and OATP1B3/MRP2 in Rat and Human Livers J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 395 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Huang, Y. Wang, and S. Grimm ATP-DEPENDENT TRANSPORT OF ROSUVASTATIN IN MEMBRANE VESICLES EXPRESSING BREAST CANCER RESISTANCE PROTEIN Drug Metab. Dispos., May 1, 2006; 34(5): 738 - 742. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
